SLC6A3 and Parkinson disease: Earlier postmortem studies reported reductions in dopamine levels, tyrosine hydroxylase (TH) expression, and dopamine transporter (DAT) binding in the striatum of MA abusers [26], and these changes paralleled neurochemical changes in Parkinson’s disease (PD) patients [27, 28].